Bicuspid Aortic Valve: Genetic and Clinical Insights

Idit Tessler, MD, MPH1,2,3 • Juliette Albuisson, MD, PhD4 • Guillaume Goudot, MD5
Shai Carmi, PhD2,3 • Shoshana Shpitzen, MSc1 • Emmanuel Messas, MD5 • Dan Gilon, MD1,2
Ronen Durst, MD1,2

1 Department of Cardiology, Hadassah Medical Center, Jerusalem, Israel
2 Faculty of Medicine, The Hebrew University, Jerusalem, Israel
3 Braun School of Public Health and Community Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
4 Oncogenetics laboratory, Centre George François Leclerc, Dijon, France
5 Cardiovascular Department, Georges Pompidou European Hospital, Paris, France

Address for correspondence Idit Tessler, MD, MPH, Department of Cardiology, Hadassah Hebrew University Medical Center, Jerusalem, 91120, POB 12000, Israel (e-mail: idit.tessler@gmail.com).

Introduction

Bicuspid aortic valve (BAV) is the most common valvular congenital heart disease, with a prevalence of 0.5 to 2% in the general population.1 BAV was first described more than 500 years ago by Leonardo da Vinci, illustrating the valve anatomy. Since data on BAV clinical significance have been established, a substantial proportion of aortic valve diseases were found to be due to BAV, regardless of a patient’s age.2 Patients with BAV have an increased risk of developing aortic valve diseases such as calcification and stenosis, regurgitation, and infective endocarditis. Aortopathies are also prevalent among BAV patients. These include coarctation of the aorta, aortic aneurysm, and dissection. BAV patients are prone to require aortic valve replacement (AVR) and aortic surgery, procedures that carry substantial risks and costs.3 Population-based studies have found a 53% risk for AVR and a 25% risk for aortic surgery during 25-year follow-up, and the risk for aortic dissection was eight times higher than in the general population.4 Moreover, the mean age for valve replacement or surgical intervention for aortic dilation is markedly younger for BAV patients compared with patients with tricuspid aortic valve.2,4 BAV was estimated to cause more morbidity and mortality than the combination of all other congenital heart defects, generating a considerable health burden to both patients and the health system.5

Keywords ► bicuspid aortic valve ► genetics ► congenital heart disease ► thoracic aortic aneurysm ► aortic dissection

Abstract

Bicuspid aortic valve (BAV) is the most common valvular congenital heart disease, with a prevalence of 0.5 to 2% in the general population. Patients with BAV are at risk for developing cardiovascular complications, some of which are life-threatening. BAV has a wide spectrum of clinical presentations, ranging from silent malformation to severe and even fatal cardiac events. Despite the significant burden on both the patients and the health systems, data are limited regarding pathophysiology, risk factors, and genetics. Family studies indicate that BAV is highly heritable, with autosomal dominant inheritance, incomplete penetrance, variable expressivity, and male predominance. Owing to its complex genetic model, including high genetic heterogeneity, only a few genes were identified in association with BAV, while the majority of BAV genetics remains obscure. Here, we review the different forms of BAV and the current data regarding its genetics. Given the clear heritability of BAV with the potential high impact on clinical outcome, the clinical value and cost effectiveness of cascade screening are discussed.
Bicuspid Aortic Valve can be classified as sporadic BAV (sporadic isolated defect), familial nonsyndromic BAV (nsBAV; in clusters within families without associated anomaly), or syndromic BAV (considered familial and associated with other anomalies including cardiovascular defects). The method of choice for diagnosis and follow-up is echocardiography (Fig. 1).

BAV clinical presentation varies significantly from a silent disease to severe life-threatening complications, even at a young age. Little is known about most dimensions of BAV, including the identity of the biochemical pathways involved in its pathogenesis. The determinants of the valve morphology and of the wide spectrum of clinical presentations and complications over time are mostly unelucidated.

Genetic data provide a very powerful and unbiased tool for understanding the basic mechanisms culminating in valve dysfunction and disease. Better understanding of the molecular processes of the disease may lead to future development of novel personalized management approaches, ultimately leading to individual risk stratification, sparing unnecessary interventions to low-risk patients, and preventing potentially fatal complications for patients at high risk.

Here, we summarize the current data regarding BAV genetics and discuss its potential clinical implication.

**Bicuspid Aortic Valve Genetics: Many Links Yet an Unsolved Riddle**

It is well established that BAV has a significant genetic component. Various studies demonstrated familial clustering of BAV. The prevalence of BAV was found to be 10-fold higher among first-degree relatives of an affected individual compared with the general population. In family studies, the heritability index for BAV, representing the degree of phenotypic variance explained by inherited rather than environmental factors, was found to be as high as 89%, suggesting marked involvement of genetic factors on disease development. Among familial BAV, most pedigrees suggest an autosomal-dominant inheritance pattern with incomplete penetrance and male predominance in a 3:1 ratio (Fig. 2). According to Mendelian genetics, autosomal-dominant inheritance pattern implies that half of first-degree relatives are expected to carry the disease-causing allele. Accounting for 50% penetrance (i.e., half of the carriers will demonstrate clinical disease), 25% of first-degree relatives are expected to be clinically affected with BAV. However, the actual rate of BAV among first-degree relatives in family studies ranges from 6 to 30%. This large range, along with the wide spectrum of structural and clinical phenotypes, is thought to be the result of the complexity of the developmental mechanisms at play in aortic valve development, involving genetic, epigenetic, and environmental factors.

A high prevalence rate of aortopathies, including aneurysm, dissection, and aortic coarctation, has been demonstrated among BAV patients and their relatives. Both the aortic root and the aortic valve have the same embryologic origin: the cardiac neural crest and the second heart field. Thoracic aortic aneurysm (TAA) frequently affects patients with BAV, or their first-degree relatives with a morphologically normal valve. TAA and BAV are thus thought to have a common genetic etiology. This observation adds support to the concept that BAV does not represent a dichotomous phenotype but would rather be integrated in a continuous spectrum of phenotypic expressions.

**Nonsyndromic Bicuspid Aortic Valve Genetics**

Since 2005, with the identification of NOTCH1 in nsBAV cases, few other genes were found to be associated with nsBAV with varying degrees of supporting evidence (Table 1). Each of these genes explains only a small percentage of the overall nsBAV prevalence and involves different molecular pathways that do not necessarily assemble into one common mechanism. In light of its high phenotypic and genotypic heterogeneity, establishing a genetic causality for BAV is challenging. Causality can only be determined when the mutation has a robust effect, the familial segregation and linkage analyses are strong, and when the association is supported by experimental and functional models.

NOTCH pathway: the first and currently single gene considered definitively causal for nsBAV is NOTCH1. NOTCH1 signaling is a highly conserved pathway of signal transduction, leading to transcription of endothelial and vascular smooth muscle cells. Altered NOTCH signaling is a well-known cause of human cardiovascular disease. NOTCH1...
Fig. 2 Examples of bicuspid aortic valve pedigrees, consistent with autosomal dominant inheritance, and low penetrance, as reflected by the limited number of clinically affected individuals.40

Fig. 3 Illustration of the underling process in bicuspid aortic valve (BAV) development. Involvement of one or more genes is the primary insult. This might be modulated by epigenetic factors, such as chromatin modifications and DNA methylation affecting genetic regulatory elements. Environmental factors, such as longstanding abnormal blood flow and hypertension, may also contribute to BAV outcome. The epigenetics illustration was modified from the ENCODE portal (https://www.encodeproject.org/).
genetic variants were demonstrated to be associated with the development of calcific aortic valve stenosis, with or without BAV. Yet, this gene is estimated to be involved in only approximately 5 to 10% of nSBAV cases, leaving the vast majority of the genetic causes of BAV unexplained. Other members of the NOTCH1 pathway (► Fig. 4) were linked to BAV and to other left-ventricular outflow tract obstruction pathologies, including mastermind-like transcriptional coactivator 1 (MAML1), rho GTPase activating protein 31 (ARHGAP31), jumonji and AT-rich interaction domain containing 2 (JARID2), and SWI/SNF-related matrix-associated actin-dependent regulator of chromatin, subfamily A, member 4 (SMARCA4).12

TGF-β Pathway: The SMAD family member 6 (SMAD6) gene encodes a signal transduction protein highly expressed in the embryonic heart and involved in many pathways, including transforming growth factor beta (TGF-β). This pathway plays a key role in vascular matrix remodeling and was linked to connective tissue disorders (► Fig. 4). The association of SMAD6 with BAV was shown by targeted

| Humans genes | Genetic approach | Mouse genes | Prevalence of BAV (%) |
|--------------|-----------------|-------------|----------------------|
| NOTCH111     | Linkage analysis| Acvr1/Alk136| 78–83                |
| GATA419      | Genome-wide association study | Gata518 | 25 |
| GATA520      | Target gene sequencing | Gata666 | 25 |
| GATA621      | Family study    | Matr347 | 12                  |
| NKX2−524     | Family study    | Nkx2−535 | 2–20                |
| TBX2014      | Copy number variation analysis | Nos332 | 42                  |
| SMAD613      | Candidate gene resequencing | Robo1/Robo233 | 100 |
| ROBO424      | Family study (whole exome sequencing) | Robo424 | 15                  |

Abbreviation: BAV, bicuspid aortic valve.
The GATA family: GATA binding protein genes encode zinc-finger transcription factors that play a role in heart valve differentiation. GATA4 was recently identified as a predisposing gene for BAV in a human genome-wide association study (GWAS) involving 466 BAV cases and 4,660 controls, with odds ratios ranging from 1.4 to 2.4 depending on the variant. Rare variants of the GATA5 gene, highly expressed in the endocardium, were also linked to nsBAV, although these results have not been consolidated in subsequent studies. A GATA6 disruptive variant was found in an nsBAV family, and in vitro studies demonstrated that GATA6 haploinsufficiency interrupts the aortic valve remodeling and extracellular matrix composition. Loss-of-function mutations in the NKX2 Homeobox 5 (NKX2.5) gene, which encodes a homeodomain-containing transcription factor that is involved in the aortic valve development, was found in a nsBAV family to disrupt the interaction between NKX2.5 and GATA5, supporting involvement of both genes in the pathology.

The roundabout guidance receptor 4 (ROBO4) gene is involved in endothelial function. Rare variants in the gene were identified by whole exome sequencing in a BAV/TAA family study.

Genetic loci linked to BAV: linkage analyses demonstrated the involvement of human chromosomal regions 18q, 5q, and 13q in BAV alone, and between BAV/TAA and human chromosomal regions 15q25–26, suggesting that uneluciated genetic defects remain to be investigated.

### Syndromic Bicuspid Aortic Valve Genetics

BAV can be syndromic, that is, presenting within a constellation of cardiac and noncardiac anomalies. The highest occurrence of BAV is found in Turner’s syndrome. Turner’s syndrome results from complete or partial missing of one X chromosome (45X). This leads to a complex developmental disorder, including cardiovascular anomalies. BAV occurs in 15 to 30% of patients and often coexists with coarctation of the aorta. The high prevalence of BAV in Turner’s syndrome may be related to high diagnostic rate due to routine cardiac imaging performed in these patients, but may also suggest X-chromosome involvement in BAV formation. This is also supported by the 3:1 male predominance found in BAV, leading to the hypothesis that X chromosome gene hemizygosity (i.e., having one copy only) is involved in BAV development.

Marfan’s syndrome (MFS) is a rather common connective tissue disorder manifesting by aortic root dilation among other phenomena. BAV was initially considered more prevalent than in the general population. A recent larger study that included more than 1,400 MFS case, has demonstrated that the prevalence of BAV was 1.8%, equivalent to the population prevalence. However, BAV presentation in MFS was associated with a more severe aortic aneurysm phenotype necessitating repair at an earlier age.

Loeys–Dietz syndromes are a group of connective tissue disorders close to MFS. These syndromic aortopathies are the consequence of abnormal TGF-β signaling, and association with BAV was demonstrated.

As illustrated here, the frequent cooccurrence of BAV and aortic aneurysms in nsBAV and in sporadic BAV, is also the rule in syndromic BAV, supporting the hypothesis that disruption of connective tissue homeostasis is related with BAV.

BAV was also described in Shone complex, a syndrome of multiple left heart obstructive lesions. Like nsBAV, it was also associated with NOTCH1 mutations. BAV is also present in other systemic disorders, such as DiGeorge’s syndrome (22q11 deletion), Down’s syndrome, and Andersen’s syndrome, at very lower frequency. The malformation is also reported in association with other isolated cardiovascular disorders including hypoplastic left heart syndrome, coarctation of the aorta, ventricular septal defects, patent ductus arteriosus, and atrial septal defects.

### Animal Models

Animal models may serve as an additional approach for understanding BAV genetics and pathophysiology. There are several mouse and Syrian hamster models for BAV, some of which were developed to support candidate genes found in humans. Of note, similarly to family studies in humans, all animal models have demonstrated incomplete penetrance and, in most cases, presented with other cardiac malformations. In some, male predominance was also observed. The main human and mouse genes involved in BAV are listed in Table 1.

Notch1 knockout (KO) mice die from cardiac malformation. These mice developed severe aortic valve calcification. Disruption of the Robo signaling pathway (Robo1 and Robo2) in transgenic mice led to BAV development. This pathway was shown to play a role in Notch regulation and was also associated with BAV in humans. The Gata gene family (Gata4, Gata5, and Gata6) was linked to BAV in mice.

### Table 2

| Syndrome          | Genetic origin | Prevalence of BAV (%) |
|-------------------|----------------|-----------------------|
| Turner’s syndrome | Monosomy X     | 15–30                 |
| Marfan’s syndrome | FBN1           | 1.8                   |
| Loeys–Dietz syndromes | TGF-β pathway | 10–30                 |
| Shone’s complex   | NOTCH1         | 50                    |
| Andersen’s syndrome | KCNJ2       | 10^4                  |

*A total of 10% genotype-positive family member presented with BAV.*
as well as in humans, leading to BAV with variable penetrance (-Table 1). Nitric oxide synthase (Nos) produces nitric oxide (NO) that has an important role in cell growth and apoptosis. Mice with induced endothelial Nos-deficiency demonstrated abnormal aortic valve development including BAV.32 A significantly reduced expression of Nos protein was demonstrated in aortic endothelial cells from BAV patients as compared with normal valve controls.34 Nkx2–5 KO mice developed BAV among other septal and valvular malformations.35 This gene is a notable example of a pleiotropic genetic effect (in which one gene leads to more than one phenotype).35 Notably, a pleiotropic effect is far more often the rule than the exception in many congenital heart disease genes. Tissue-specific KO of activin A receptor type 1 (Acvrf1) resulted in aortic valve disorders including BAV, supporting the gene’s role in valvular development as seen in TAAD/BAV human cases.36 However, there is not a full correspondence between the genetic landscapes in mice and in humans. As an example, ROBO4 has been involved in BAV/TAA in humans at heterozygous state with high penetrance (15%) with a variety of aortic valve defects.24

**Bicuspid Aortic Valve Phenotypes: Sievers Classification**

Anatomically the bicuspid valve morphology phenotypes are classified according to the cusp’s fusion. A “pure” form of BAV consists of two cusps of equal size with no raphe between them and is relatively rare, while the more common configuration of bicuspid valve consists of two unequal cusps, the larger one characterized by a raphe formed between the two fused cusps. A rare form of unicuspival valve is also found. The BAV morphology type is usually defined by echocardiography and is classified according to Sievers classification as follows: type 0 (no raphe); type 1 (one raphe) with subtypes (1) 1 LR for left–right coronary cusps fusion, (2) 1 RN for right and noncoronary, and (3) 1 NL for noncoronary and left coronary cusps; and type 2 (two raphes). Each morphology type is associated with different pathologies of the valve and the aorta, and may even affect prognosis.37 It was hypothesized that the different types developed from distinct embryological origins.38 Our data, as well as previously published data, show, in a large set of pedigrees, that different BAV types are present in a family.39,40 To date, no correlation between Sievers type BAV and genetic status was demonstrated. This, once again, highlights the complexity of BAV genetics and phenotypic variability.

**Cascade Screening: What Is the Clinical Utility?**

High heritability of BAV raises the question of “cascade screening” of relatives of a BAV case. Cascade screening is a method to identify individuals at risk for a genetic condition by the process of systematic screening of first-degree relatives of the index case. The 2014 American College of Cardiology (AHA/ACC) valvular heart disease guidelines recommend clinical screening of first-degree relatives only if the patient with BAV has an associated aortopathy or a family history of valvular heart disease or aortopathy.41 There is no clear recommendation, however, for screening in patients with noncomplicated BAV. The European Society of Cardiology and the European Association for Cardio-Thoracic Surgery guidelines for the management of valvular heart disease consider BAV as a risk factor for aortic regurgitation and suggest echocardiographic screening of first-degree relatives.42 The Canadian Cardiovascular Society indicated screening by echocardiography of first-degree relatives of bicuspid patients, including screening of family members in the pediatric age range.43 The screening examination by echocardiography itself does not involve any risk for the patient. It can detect BAV or associated pathologies at an early stage and hence prevent complications. This, however, may come at a considerable emotional burden to the families. As described above, 6 to 30% of first-degree relatives are expected to have BAV or related anomaly. It is currently not clear how many of these will clinically benefit from familial screening. Cost analysis studies have demonstrated a significant cost-effectiveness for echocardiography screening.44,45 Additional studies are needed to establish the best terms and timing of the optimal screening program.

**Conclusion**

Even after more than 500 years of its first description by Leonardo da Vinci, BAV still poses a great challenge to clinicians. It presents with a wide clinical and structural phenotypic spectrum, from a silent malformation to a severe complicated disease with significant morbidity and mortality. Biological research to understand BAV and its cause, as in other cardiac malformations, is very active since the discovery of NOTCH1 role in BAV. Complimentary genetic approaches, including association, linkage, and candidate-gene studies, have allowed identification of few other genes, accounting for only a small fraction of the genetic weight in the disease, and our understanding remains very limited. This is probably explained by a complex developmental process. Epigenetic and microenvironmental factors might weight more significantly than expected, unveiling complex inheritance including polygenic involvement. Deciphering genetic models of BAV is now the new challenge, aiming at the objective of optimizing patient’s risk stratification and clinical management according to the individual risk.

**Funding**

The study was supported by the Hadassah-Franch Association and the Center for Interdisciplinary Data Science Research of the Hebrew University.

**Conflict of interest**

The authors declare no conflict of interest related to this article.
Acknowledgment

Dr. Tessler thanks Ilai Ovadia for his contribution in designing the figures.

References

1. Braverman AC. The bicuspid aortic valve and associated aortic disease. In: Otto CM, Bonow RO, eds. Valvular Heart Disease. 4th ed. Philadelphia, PA: Saunders/Elsevier; 2013:179–198

2. Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation 2005;111(07):920–925

3. Tzemos N, Therrien J, Yip J, et al. Outcomes in adults with bicuspid aortic valves. JAMA 2008;300(11):1317–1325

4. Micheletta HI, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA 2011;306(10):1104–1112

5. Ward C. Clinical significance of the bicuspid aortic valve. Heart 2000;83(01):81–85

6. Loscalzo ML, Goh DLM, Loeys B, Kent KC, Spevak PJDH, Dietz HC. Familial thoracic aortic dilation and bicuspid aortic valve: a prospective analysis of natural history and inheritance. Am J Med Genet A 2007;143A(17):1960–1967

7. Cripe L, Andel FG, Bové AA. Bicuspid aortic valve: a neglected feature of Shone's complex? Pediatr Cardiol 2014;35(01):186–187

8. Milleron O, Ropers J, Arnault F, et al. Clinical significance of aortic root modification associated with bicuspid aortic valve in Marfan syndrome. Circ Cardiovasc Imaging 2019;12(03):e008129

9. Estévez TBX20 as a contributing gene. Eur J Hum Genet 2015;23(04):248–272

10. Marian AJ. Causality in genetics: the gradient of genetic effects and back to Koch's postulates of causality. Circ Res 2014;114(02):e18–e21

11. Varg G, Muth AN, Ransom JF, et al. Mutations in NOTCH1 cause familial thoracic aortic dilation and bicuspid aortic valve-related aortopathy identified in the homeobox gene Nkx2-5. Circulation 2010;117(23):2789–2800

12. Martin PS, Kloesel B, Norris RA, Lindsay M, Milan D, Body SC. Embryonic development of the bicuspid aortic valve. J Cardiovasc Dev Dis 2015;2(04):248–272

13. Gillis E, Kumar AA, Luyckx I, et al. Mibava Leducq Consortium. Candidate gene resequencing in a large bicuspid aortic valve-associated thoracic aortic aneurysm cohort: SMAD6 as an important contributor. Front Physiol 2017;8:400

14. Luyckx I, Kumar AA, Reyniers E, et al. MIBAVA Leducq Consortium. Copy number variation analysis in bicuspid aortic valve-related aortopathy identifies TBX20 as a contributing gene. Eur J Hum Genet 2019;27(07):1033–1043

15. de Pater E, Ciampricotti M, Priller F, et al. Bmp signaling exerts opposite effects on cardiac differentiation. Circ Res 2012;110(04):578–587

16. van den Laar IMBH, van der Linde D, Oei EHG, et al. Phenotypic spectrum of the SMAD3-related aneurysms-osteopathia syndrome. J Med Genet 2012;49(01):47–57

17. Bertoli-Avella AM, Gillis E, Morisaki H, et al. Mutations in a TGF-β ligand, TGFβ3, cause syndromic aortic aneurysms and dissections. J Am Coll Cardiol 2015;65(13):1324–1336

18. Laforet B, Andelfinger G, Nemer M. Loss of GATA5 in mice leads to bicuspid aortic valve. J Clin Invest 2011;121(07):2876–2887

19. Yang B, Zhou W, Jiao J, et al. Protein-altering and regulatory genetic variants near GATA4 implicated in bicuspid aortic valve. Nat Commun 2017;8:15481

20. Padang R, Bagnall RD, Richmond DR, Bannon PG, Semsarian C. Rare non-synonymous variations in the transcriptional activation domains of GATA5 in bicuspid aortic valve disease. J Mol Cell Cardiol 2012;53(02):277–281

21. Xu V-J, Di R-M, Qiao Q, et al. GATA6 loss-of-function mutation contributes to congenital bicuspid aortic valve. Gene 2018;663:115–120

22. Gharibeh L, Komati H, Bossé Y, et al; Bicuspid Aortic Valve Consortium. GATA6 regulates aortic valve remodeling, and its haploinsufficiency leads to right-left type bicuspid aortic valve. Circulation 2018;138(10):1025–1038

23. Qu X-K, Qiu X-B, Yuan F, et al. A novel NKKX2.5 loss-of-function mutation associated with congenital bicuspid aortic valve. Am J Cardiol 2014;114(12):1891–1895

24. Gould RA, Aziz H, Woods CE, et al; Baylor-Hopkins Center for Mendelian Genomics MIBAVA Leducq Consortium. ROBO4 variants predispose individuals to bicuspid aortic valve and thoracic aortic aneurysm. Nat Genet 2019;51(01):42–50

25. Martin LJ, Ramachandran V, Cripe LH, et al. Evidence in favor of linkage to human chromosomal regions 18q, 5q and 13q for bicuspid aortic valve and associated cardiovascular malformations. Hum Genet 2007;121(02):275–284

26. Mortensen KH, Andersen NH, Gravholt CH. Cardiovascular phenotype in Turner syndrome–integrating cardiology, genetics, and endocrinology. Endocr Rev 2012;33(05):677–714

27. Nistri S, Porciani MC, Attanasio M, Abbate R, Ginsfält G, Pepe P. Association of Marfan syndrome and bicuspid aortic valve: frequency and outcome. Int J Cardiol 2012;155(02):324–325

28. Prakash SK, Bossé Y, Muehlshlegel JD, et al; BAVCon Investigators. A roadmap to investigate the genetic basis of bicuspid aortic valve and its complications: insights from the International BAVCon (Bicuspid Aortic Valve Consortium). J Am Coll Cardiol 2014;64(08):832–839

29. Lee TC, Zhao YD, Courtman DW, Stewart DJ. Abnormal aortic valve development in mice lacking endothelial nitric oxide synthase. Circulation 2000;101(20):2345–2348

30. Mommersteeg MTM, Yeh ML, Parnavelas GJ, Andrews WD. Disrupted Slit-Robo signalling results in membranous ventricular septum defects and bicuspid aortic valves. Cardiovasc Res 2015;106(01):55–66

31. Aicher D, Urbich C, Zeiher A, Dimmeler S, Schäfers H-J. Endothelial nitric oxide synthase in bicuspid aortic valve disease. Ann N Y Acad Sci 2007;1122:1290–1294

32. Biben C, Weber R, Kesteven S, et al. Cardiac septal and valvular dysmorphogenesis in mice heterozygous for mutations in the homeobox gene Nkx2-5. Circ Res 2000;87(04):888–895

33. Thomas PS, Sridurongrit S, Ruiz-Lozano P, Kaartinen V. Deficient signaling via Alk2 (Acvr1) leads to bicuspid aortic valve development. PLoS One 2012;7(04):e35539

34. Schaefer BM, Lewin MB, Stout KK, et al. The bicuspid aortic valve: an integrated phenotypic classification of leaflet morphology and aortic root shape. Heart 2008;94(12):1634–1638

35. Fernández B, Durán AC, Fernández-Gallego T, et al. Bicuspid aortic valves with different spatial orientations of the leaflets are distinct etiological entities. J Am Coll Cardiol 2009;54(24):2312–2318

36. Robledo-Carmona J, Rodríguez-Bailón I, Carrasco-Chinchilla F, et al. Hereditary patterns of bicuspid aortic valve in Marfan syndrome. J Med Genet 2013;50(04):3443–3449

37. Tessler I, Goudot G, Albujuiss J, et al. Is bicuspid aortic valve, morphology genetically determined? A family-based study. Am J Cardiol 2021(e-pub ahead of print). Doi: 10.1016/j.amjcard.2021.09.051

38. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: A report of the American college of cardiology/American heart
association task force on practice guidelines. Circulation 2014; 129(23):2440–2492
42 Baumgartner H, Falk V, Bax JJ, et al; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017;38(36):2739–2791
43 Boodhwani M, Andelfinger G, Leipsic J, et al; Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement on the management of thoracic aortic disease. Can J Cardiol 2014;30(06):577–589
44 Tessler I, Leshno M, Shmueli A, Shpitzen S, Durst R, Gilon D. Cost-effectiveness analysis of screening for first-degree relatives of patients with bicuspid aortic valve. Eur Heart J Qual Care Clin Outcomes 2021;7(05):447–457
45 Hales AR, Mahle WT. Echocardiography screening of siblings of children with bicuspid aortic valve. Pediatrics 2014;133(05): e1212–e1217
46 Laforest B, Nemer M. GATA5 interacts with GATA4 and GATA6 in outflow tract development. Dev Biol 2011;358(02):368–378
47 Quintero-Rivera F, Xi QJ, Keppler-Noreuil KM, et al. MATR3 disruption in human and mouse associated with bicuspid aortic valve, aortic coarctation and patent ductus arteriosus. Hum Mol Genet 2015;24(08):2375–2389
48 Guo B, McMillan BJ, Blacklow SC. Structure and function of the Mind bomb E3 ligase in the context of Notch signal transduction. Curr Opin Struct Biol 2016;41:38–45